Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.37 |
| ▸ | PLD2 | O14939 | 2/20 | 0.34 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447753 | 0.93 | BACE1 (0.43) | BACE1PLD2PLD1 | |
| SCHEMBL448245 | 0.86 | AKR1B1 (0.34) | BACE1PLD2PLD1OPRM1DPP4 | |
| SCHEMBL448810 | 0.80 | BACE1 (0.43) | BACE1 | |
| SCHEMBL446718 | 0.73 | BACE1 (0.50) | BACE1 | |
| SCHEMBL448182 | 0.70 | ACHE (0.46) | BACE1 | |
| SCHEMBL445942 | 0.67 | BACE1 (0.48) | BACE1 | |
| SCHEMBL429267 | 0.66 | BACE1 (0.45) | BACE1 | |
| SCHEMBL10272228 | 0.66 | BACE1 (0.45) | BACE1 | |
| SCHEMBL446114 | 0.66 | BACE1 (0.45) | BACE1 | |
| SCHEMBL427967 | 0.66 | BACE1 (0.45) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885PLD2 3804/4885PLD1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.